Forskning ved Københavns Universitet - Københavns Universitet

Forside

Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. / Tukahebwa, Edridah M.; Vennervald, Birgitte J; Nuwaha, Fred; Kabatereine, Narcis B.; Magnussen, Pascal.

I: Transactions of the Royal Society of Tropical Medicine and Hygiene, Bind 107, Nr. 6, 2013, s. 397-404.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Tukahebwa, EM, Vennervald, BJ, Nuwaha, F, Kabatereine, NB & Magnussen, P 2013, 'Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda', Transactions of the Royal Society of Tropical Medicine and Hygiene, bind 107, nr. 6, s. 397-404. https://doi.org/10.1093/trstmh/trt024

APA

Tukahebwa, E. M., Vennervald, B. J., Nuwaha, F., Kabatereine, N. B., & Magnussen, P. (2013). Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 107(6), 397-404. https://doi.org/10.1093/trstmh/trt024

Vancouver

Tukahebwa EM, Vennervald BJ, Nuwaha F, Kabatereine NB, Magnussen P. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2013;107(6):397-404. https://doi.org/10.1093/trstmh/trt024

Author

Tukahebwa, Edridah M. ; Vennervald, Birgitte J ; Nuwaha, Fred ; Kabatereine, Narcis B. ; Magnussen, Pascal. / Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. I: Transactions of the Royal Society of Tropical Medicine and Hygiene. 2013 ; Bind 107, Nr. 6. s. 397-404.

Bibtex

@article{f044a1390fbf4a7e876655f927de4383,
title = "Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda",
abstract = "BACKGROUND: The current recommended control strategy for schistosomiasis is annual treatment using 40 mg/kg of praziquantel. However, praziquantel is only effective on adult worms and giving a second dose may increase its efficacy. We assessed the effect of one versus two doses of praziquantel on cure rate and re-infection with Schistosoma mansoni in a high endemic community along Lake Victoria, Uganda. METHODOLOGY: To investigate the effect of the two regimens, 395 infected people were randomised into two groups; one received a single standard dose of praziquantel (Distocide{\circledR} 600 mg, Shin Poong Pharmaceuticals, Seoul, Republic of Korea), 40mg/kg body weight, while the other group received a second dose 2 weeks later. Cure rate and infection intensity were assessed 9 weeks after the first treatment using standard parasitological procedures. Re-infection levels were monitored 8 and 24 months after treatment. RESULTS: Those who received two doses were more likely to be cured (69.7{\%}) compared to those who received a single dose (47.9{\%}) (¿(2) = 18.5, p <0.001). Geometric mean intensity (GMI) of infection at 9 weeks (eggs per gram of faeces [epg]) was 12.0 epg (CI95: 8.9-16.1) for individuals who received 2 doses and 22.1 epg (CI95: 16.9-28.8) for those in the single dose arm. Eight months after treatment, prevalence of re-infection for individuals in the double dose arm (61.6{\%}, CI95: 50.2-73.1) was not significantly different from that of those in a single dose arm (68.3{\%}, CI95: 59.9-76.8). The difference in GMI of re-infection for individuals in the single dose arm (33.8 epg, CI95: 23.2-49.3) and those in the double dose arm (34.5 epg, CI95: 24.7-48.1) was not significant. Twenty four months after treatment, prevalence of re-infection was not significantly different. The difference in GMI of re-infection for those in the single dose arm (57.5 epg, CI95: 33.9-97.5) and those in the double dose arm (42.2 epg, CI95: 29.9-59.6) was also insignificant. CONCLUSION: Our results suggest that a second dose of praziquantel given 2 weeks after the first dose improves cure rate and reduces S. mansoni infection intensity. However, there is no added advantage on reduction of S. mansoni re-infection by administering two doses of praziquantel. CLINICAL TRIALS.GOV IDENTIFIER: NCT00215267.",
keywords = "Former LIFE faculty, Schistisoma mansoni, Cure rate, Re-infection, Uganda",
author = "Tukahebwa, {Edridah M.} and Vennervald, {Birgitte J} and Fred Nuwaha and Kabatereine, {Narcis B.} and Pascal Magnussen",
year = "2013",
doi = "10.1093/trstmh/trt024",
language = "English",
volume = "107",
pages = "397--404",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda

AU - Tukahebwa, Edridah M.

AU - Vennervald, Birgitte J

AU - Nuwaha, Fred

AU - Kabatereine, Narcis B.

AU - Magnussen, Pascal

PY - 2013

Y1 - 2013

N2 - BACKGROUND: The current recommended control strategy for schistosomiasis is annual treatment using 40 mg/kg of praziquantel. However, praziquantel is only effective on adult worms and giving a second dose may increase its efficacy. We assessed the effect of one versus two doses of praziquantel on cure rate and re-infection with Schistosoma mansoni in a high endemic community along Lake Victoria, Uganda. METHODOLOGY: To investigate the effect of the two regimens, 395 infected people were randomised into two groups; one received a single standard dose of praziquantel (Distocide® 600 mg, Shin Poong Pharmaceuticals, Seoul, Republic of Korea), 40mg/kg body weight, while the other group received a second dose 2 weeks later. Cure rate and infection intensity were assessed 9 weeks after the first treatment using standard parasitological procedures. Re-infection levels were monitored 8 and 24 months after treatment. RESULTS: Those who received two doses were more likely to be cured (69.7%) compared to those who received a single dose (47.9%) (¿(2) = 18.5, p <0.001). Geometric mean intensity (GMI) of infection at 9 weeks (eggs per gram of faeces [epg]) was 12.0 epg (CI95: 8.9-16.1) for individuals who received 2 doses and 22.1 epg (CI95: 16.9-28.8) for those in the single dose arm. Eight months after treatment, prevalence of re-infection for individuals in the double dose arm (61.6%, CI95: 50.2-73.1) was not significantly different from that of those in a single dose arm (68.3%, CI95: 59.9-76.8). The difference in GMI of re-infection for individuals in the single dose arm (33.8 epg, CI95: 23.2-49.3) and those in the double dose arm (34.5 epg, CI95: 24.7-48.1) was not significant. Twenty four months after treatment, prevalence of re-infection was not significantly different. The difference in GMI of re-infection for those in the single dose arm (57.5 epg, CI95: 33.9-97.5) and those in the double dose arm (42.2 epg, CI95: 29.9-59.6) was also insignificant. CONCLUSION: Our results suggest that a second dose of praziquantel given 2 weeks after the first dose improves cure rate and reduces S. mansoni infection intensity. However, there is no added advantage on reduction of S. mansoni re-infection by administering two doses of praziquantel. CLINICAL TRIALS.GOV IDENTIFIER: NCT00215267.

AB - BACKGROUND: The current recommended control strategy for schistosomiasis is annual treatment using 40 mg/kg of praziquantel. However, praziquantel is only effective on adult worms and giving a second dose may increase its efficacy. We assessed the effect of one versus two doses of praziquantel on cure rate and re-infection with Schistosoma mansoni in a high endemic community along Lake Victoria, Uganda. METHODOLOGY: To investigate the effect of the two regimens, 395 infected people were randomised into two groups; one received a single standard dose of praziquantel (Distocide® 600 mg, Shin Poong Pharmaceuticals, Seoul, Republic of Korea), 40mg/kg body weight, while the other group received a second dose 2 weeks later. Cure rate and infection intensity were assessed 9 weeks after the first treatment using standard parasitological procedures. Re-infection levels were monitored 8 and 24 months after treatment. RESULTS: Those who received two doses were more likely to be cured (69.7%) compared to those who received a single dose (47.9%) (¿(2) = 18.5, p <0.001). Geometric mean intensity (GMI) of infection at 9 weeks (eggs per gram of faeces [epg]) was 12.0 epg (CI95: 8.9-16.1) for individuals who received 2 doses and 22.1 epg (CI95: 16.9-28.8) for those in the single dose arm. Eight months after treatment, prevalence of re-infection for individuals in the double dose arm (61.6%, CI95: 50.2-73.1) was not significantly different from that of those in a single dose arm (68.3%, CI95: 59.9-76.8). The difference in GMI of re-infection for individuals in the single dose arm (33.8 epg, CI95: 23.2-49.3) and those in the double dose arm (34.5 epg, CI95: 24.7-48.1) was not significant. Twenty four months after treatment, prevalence of re-infection was not significantly different. The difference in GMI of re-infection for those in the single dose arm (57.5 epg, CI95: 33.9-97.5) and those in the double dose arm (42.2 epg, CI95: 29.9-59.6) was also insignificant. CONCLUSION: Our results suggest that a second dose of praziquantel given 2 weeks after the first dose improves cure rate and reduces S. mansoni infection intensity. However, there is no added advantage on reduction of S. mansoni re-infection by administering two doses of praziquantel. CLINICAL TRIALS.GOV IDENTIFIER: NCT00215267.

KW - Former LIFE faculty

KW - Schistisoma mansoni

KW - Cure rate

KW - Re-infection

KW - Uganda

U2 - 10.1093/trstmh/trt024

DO - 10.1093/trstmh/trt024

M3 - Journal article

C2 - 23596262

VL - 107

SP - 397

EP - 404

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 6

ER -

ID: 45260692